Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease
(2005) In Dementia and Geriatric Cognitive Disorders 20(6). p.367-374- Abstract
- We have recently reported that a polymorphism in the cell division cycle (CDC2) gene, designated Ex6 + 7I/D, is associated with Alzheimer's disease (AD). The CDC2 gene is located on chromosome 10q21.1 close to the marker D10S1225 linked to AD. Active cdc2 accumulates in neurons containing neurofibrillary tangles (NFT), a process that can precede the formation of NFT. Therefore, CDC2 is a promising candidate susceptibility gene for AD. We investigated the possible effects of the CDC2 polymorphism on cerebrospinal fluid (CSF) biomarkers in AD patients. CDC2 genotypes were evaluated in relation to CSF protein levels of total tau, phospho-tau and beta-amyloid (1-42) in AD patients and control individuals, and in relation to the amount of... (More)
- We have recently reported that a polymorphism in the cell division cycle (CDC2) gene, designated Ex6 + 7I/D, is associated with Alzheimer's disease (AD). The CDC2 gene is located on chromosome 10q21.1 close to the marker D10S1225 linked to AD. Active cdc2 accumulates in neurons containing neurofibrillary tangles (NFT), a process that can precede the formation of NFT. Therefore, CDC2 is a promising candidate susceptibility gene for AD. We investigated the possible effects of the CDC2 polymorphism on cerebrospinal fluid (CSF) biomarkers in AD patients. CDC2 genotypes were evaluated in relation to CSF protein levels of total tau, phospho-tau and beta-amyloid (1-42) in AD patients and control individuals, and in relation to the amount of senile plaques and NFT in the frontal cortex and in the hippocampus in patients with autopsy-proven AD and controls. The CDC2 Ex6 + 7I allele was associated with a gene dose-dependent increase of CSF total tau levels (F-2,F- 626 = 7.0, p = 0.001) and the homozygous CDC2Ex6 +7II genotype was significantly more frequent among AD patients compared to controls (p = 0.006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/898726
- author
- Johansson, A ; Zetterberg, H ; Hampel, H ; Buerger, K ; Prince, JA ; Minthon, Lennart LU ; Wahlund, LO and Blennow, K
- organization
- publishing date
- 2005
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, CDC2, cell cycle, tau, beta-amyloid
- in
- Dementia and Geriatric Cognitive Disorders
- volume
- 20
- issue
- 6
- pages
- 367 - 374
- publisher
- Karger
- external identifiers
-
- pmid:16192727
- wos:000233364300006
- scopus:27844601188
- ISSN
- 1420-8008
- DOI
- 10.1159/000088634
- language
- English
- LU publication?
- yes
- id
- 2905f06f-3680-43fd-9dd2-e239ffe5ae05 (old id 898726)
- date added to LUP
- 2016-04-01 12:22:16
- date last changed
- 2022-01-27 02:48:42
@article{2905f06f-3680-43fd-9dd2-e239ffe5ae05, abstract = {{We have recently reported that a polymorphism in the cell division cycle (CDC2) gene, designated Ex6 + 7I/D, is associated with Alzheimer's disease (AD). The CDC2 gene is located on chromosome 10q21.1 close to the marker D10S1225 linked to AD. Active cdc2 accumulates in neurons containing neurofibrillary tangles (NFT), a process that can precede the formation of NFT. Therefore, CDC2 is a promising candidate susceptibility gene for AD. We investigated the possible effects of the CDC2 polymorphism on cerebrospinal fluid (CSF) biomarkers in AD patients. CDC2 genotypes were evaluated in relation to CSF protein levels of total tau, phospho-tau and beta-amyloid (1-42) in AD patients and control individuals, and in relation to the amount of senile plaques and NFT in the frontal cortex and in the hippocampus in patients with autopsy-proven AD and controls. The CDC2 Ex6 + 7I allele was associated with a gene dose-dependent increase of CSF total tau levels (F-2,F- 626 = 7.0, p = 0.001) and the homozygous CDC2Ex6 +7II genotype was significantly more frequent among AD patients compared to controls (p = 0.006, OR = 1.57, 95% CI 1.13-2.17). Our results provide further evidence for an involvement of cdc2 in the pathogenesis of AD.}}, author = {{Johansson, A and Zetterberg, H and Hampel, H and Buerger, K and Prince, JA and Minthon, Lennart and Wahlund, LO and Blennow, K}}, issn = {{1420-8008}}, keywords = {{Alzheimer's disease; CDC2; cell cycle; tau; beta-amyloid}}, language = {{eng}}, number = {{6}}, pages = {{367--374}}, publisher = {{Karger}}, series = {{Dementia and Geriatric Cognitive Disorders}}, title = {{Genetic association of CDC2 with cerebrospinal fluid tau in Alzheimer's disease}}, url = {{http://dx.doi.org/10.1159/000088634}}, doi = {{10.1159/000088634}}, volume = {{20}}, year = {{2005}}, }